Welcome to our dedicated page for Evofem Bioscienc news (Ticker: EVFM), a resource for investors and traders seeking the latest updates and insights on Evofem Bioscienc stock.
Evofem Biosciences, Inc. (OTC: EVFM) regularly issues news and updates focused on women’s sexual and reproductive health, its FDA-approved products, and its corporate strategy. Company press releases highlight developments around PHEXXI, a hormone-free, on-demand prescription contraceptive vaginal gel, and SOLOSEC, a single-dose oral antimicrobial treatment for bacterial vaginosis and trichomoniasis.
News items cover a range of topics, including quarterly and annual financial results, cost-of-goods initiatives, and progress on international expansion. For example, Evofem has announced licensing arrangements with Pharma 1 Drug Store in the Middle East and North Africa, regulatory submissions for PHEXXI and SOLOSEC in the United Arab Emirates, and steps toward commercialization in Gulf Cooperation Council states. These updates provide context on how the company is seeking to diversify and expand its revenue stream beyond the United States.
Evofem’s releases also describe marketing and educational campaigns such as the "Say Vagina" initiative, which the company presents as an effort to normalize clinical language and address stigma around vaginal health. Other news has detailed the impact of social media campaigns on traffic to the PHEXXI website, engagement from healthcare providers, and broader brand awareness.
In addition, investors can find news about corporate actions and governance, including information on a previously proposed merger with Aditxt, Inc. and its subsequent termination, reverse stock split authorization, and capital raises through notes and warrants. This news page aggregates such announcements so readers can follow product, regulatory, commercial, and corporate developments related to Evofem Biosciences and its EVFM stock symbol over time.
Evofem Biosciences (NASDAQ: EVFM) announced positive results from its Phase 2b AMPREVENCE trial at the 2020 STD Prevention Virtual Conference. The trial evaluated EVO100 for preventing urogenital chlamydia and gonorrhea in women, achieving a 50% risk reduction for chlamydia and 78% for gonorrhea compared to placebo. The product was well tolerated by participants. Following this success and a favorable FDA data review, Evofem plans to initiate a Phase 3 trial in Q4 2020, demonstrating the potential impact of EVO100 on women's health amid rising STI rates in the U.S.
Evofem Biosciences (NASDAQ: EVFM) announced the U.S. launch of Phexxi™, the first non-hormonal prescription vaginal gel for on-demand contraception. Approved by the FDA on May 22, 2020, Phexxi maintains vaginal pH to prevent sperm viability. The product will be marketed in boxes of 12 applicators. Evofem also introduced the Phexxi Concierge Experience, a telemedicine support system for prescription access and counseling. Financial assistance will allow eligible women to purchase Phexxi with low co-pays. Notably, Phexxi does not prevent STIs and may have side effects.
Evofem Biosciences (NASDAQ: EVFM) announced its participation in four healthcare equity conferences in September 2020. The events include:
- H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 14
- 2020 Cantor Global Virtual Healthcare Conference on September 16
- Morgan Stanley 18th Annual Global Healthcare Conference on September 18
- Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22
Evofem Biosciences (NASDAQ: EVFM) announced on August 18, 2020, that its Compensation Committee approved stock option awards for 60 new employees, totaling 319,200 shares of common stock. The options have an exercise price of $3.35 and a 10-year term, vesting over four years. This grant aligns with the company's 2018 Inducement Equity Incentive Plan intended to attract new talent. Evofem focuses on developing products for women's sexual and reproductive health, with its leading product, Phexxi™, being the first hormone-free contraceptive gel approved in the U.S.
Evofem Biosciences (NASDAQ: EVFM) reported its Q2 2020 financial results, highlighting the FDA approval of Phexxi, a contraceptive, and raising over $130 million in gross proceeds from financing. The company is set for Phexxi's commercial launch in September. Key highlights included a net loss of $52.7 million, or $(0.91) per share, compared to $(0.97) per share in Q2 2019, while unrestricted cash stood at $123.6 million. Guidance for 2020 remains unchanged, projecting sales and marketing expenses of $63 to $68 million and cash burn of $36 to $44 million in Q4.
Evofem Biosciences, Inc. (NASDAQ: EVFM) announced that CEO Saundra Pelletier has been named to the PharmaVOICE 100 list of the most inspiring people in life sciences. Recognized for her leadership in advancing women's sexual and reproductive health, Pelletier led the company through its public market transition and secured over $400 million in financing. Evofem is also advancing EVO100 into Phase 3 trials for the prevention of chlamydia and gonorrhea in women. This recognition reflects both her personal resilience and commitment to innovative health solutions.
Evofem Biosciences (NASDAQ: EVFM) will host a webcast and conference call on August 4, 2020, at 11:00 a.m. EDT to discuss its second quarter financial results and business updates for the period ending June 30, 2020. Interested participants can dial in at (866) 503-5561 (U.S. toll-free) or (253) 336-2965, using conference ID 5884198. A replay will be available post-call until August 7, 2020. The live webcast can be accessed via the Company's Investor page.
Evofem Biosciences (NASDAQ: EVFM) issued a letter to stockholders detailing key achievements and future plans for 2020. Highlights include FDA approval of Phexxi, a non-hormonal contraceptive, and plans for its commercial launch in September. Evofem is also preparing for a Phase 3 trial for EVO100 aimed at preventing chlamydia and gonorrhea. The company raised approximately $136 million recently, strengthening its financial position. Despite challenges, Evofem remains focused on addressing unmet needs in women's health and driving stockholder value.